CDK9-IN-7

Overview

CDK9-IN-7 (compound 21e) is a selective, highly potent, and orally active CDK9/cyclin T inhibitor ( IC 50 =11 nM), which exhibits more potent over other CDKs (CDK4/cyclinD=148 nM; CDK6/cyclinD=145 nM). CDK9-IN-7 shows antitumor activity without obvious toxicity. CDK9-IN-7 induces NSCLC cell apoptosis , arrests the cell cycle in the G2 phase, and suppresses the stemness properties of NSCLC.

Application

Products | Products > Signaling Pathways > Cell Cycle/DNA Damage | Products > Signaling Pathways > Apoptosis | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Drug Resistance | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > CDK | Products > Signaling Pathways > Apoptosis

Product Information

• Catalog No.: HY-126251
• CAS No.: 2369981-71-3
• Molecular Formula: C29H37N7O2S
• Molecular Weight: 547.71
• Purity: 98.05%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
• Solubility: ≥ 2.08 mg/mL (3.80 mM); Clear solution
• Availability: In-stock

Source

Original product source